BridgeBio Pharma BBIO Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's operating cash flow?
- BridgeBio Pharma (BBIO) reported operating cash flow of -$197.28M in Q1 2026.
- How has BridgeBio Pharma's operating cash flow changed year-over-year?
- BridgeBio Pharma's operating cash flow increased by 1.0% year-over-year, from -$199.24M to -$197.28M.
- What is the long-term trend for BridgeBio Pharma's operating cash flow?
- Over 3 years (2021 to 2025), BridgeBio Pharma's operating cash flow has grown at a -3.6% compound annual growth rate (CAGR), from -$497.93M to -$445.91M.
- What does operating cash flow mean?
- The net cash flow resulting from the company's day-to-day business activities.
- How do you interpret operating cash flow?
- Positive values indicate self-sustaining operations, while negative values suggest a reliance on external financing to fund ongoing research or operations.
- How does operating cash flow compare across companies?
- Early-stage biotech companies typically report negative values due to heavy R&D investment.